medigraphic.com

2008, Número 4

<< Anterior Siguiente >>

Arch Cardiol Mex 2008; 78 (4)


Actividades paraoxonasa y arilesterasa bajas en sujetos mexicanos con enfermedad arterial coronaria

Gamboa R, Regalado JC, Huesca-Gómez C, Posadas-Romero C, Verdejo Paris J, Vargas-Alarcón G, Pérez-Méndez O

Idioma: Español
Referencias bibliográficas: 41
Paginas: 360-368
Archivo PDF: 140.76 Kb.


RESUMEN

Propósito: Determinar la actividad de la enzima paraoxonasa-1 (PON1), y sus feno- y genotipos en posición 192 de la cadena de aminoácidos en sujetos mexicanos con diagnóstico de enfermedad arterial coronaria (EAC). Métodos: El polimorfismo de la PON1-192 se determinó por PCR-RFLP, y la actividad PON1 en suero se estableció utilizando dos substratos, paraoxón (actividad PONasa) o fenilacetato (denominada actividad ARE), en 155 individuos clínicamente sanos (grupo control), y en 155 pacientes con enfermedad cardiovascular que habían sufrido al menos un infarto (grupo EAC). Los sujetos en el estudio fueron clasificados de acuerdo a su fenotipo bioquímico como AA, AB y BB si el cociente de la actividad PONasa estimulada con NaCl 1M dividida por la actividad ARE era ‹ 2, entre 2 y 8, y › 8, respectivamente. Resultados: Las actividades PONasa y ARE fueron significativamente menores en los pacientes con EAC en relación con los sujetos control (233.1 ± 102.1 vs 295.8 ± 159.1 nmol/min/mL, y 103.1 ± 33.7 vs 220.2 ± 120.7 micromol/min/mL, respectivamente, p ‹ 0.05 para ambos). Las frecuencias tanto alélicas como genotípicas de PON1-192 fueron similares en ambos grupos. Además, en nuestro estudio el genotipo PON1-192 Q/R no corresponde con el fenotipo bioquímico A/B como se había propuesto anteriormente por otros autores. Conclusiones: Los sujetos mexicanos con EAC presentan actividades PON1 menores que los individuos control, sugiriendo que la actividad PON1, podría ser marcador de riesgo de EAC, mientras que el genotipo PON1-192 carece de valor informativo en la evaluación de dicho riesgo en esta población en particular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Assmann G, Schulte H, von Eckardstein, A, Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11-S20.

  2. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohon SD, Schaefer MM, Castelli WP, et al: Factors associated with low and elevated plasma high-density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871-882.

  3. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN: Human serum Paraoxonase/Arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 2214-2225.

  4. Mackness M, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.

  5. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.

  6. Mackness M, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.

  7. Li WF, Costa LG, Richter RJ, Hagen T, Shih TM, Tward A, et al: Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10: 767-779.

  8. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, et al: Evidence for association for paraoxonase gene polymorphisms and atherosclerotic disease. Atherosclerosis 2000; 149: 435-442.

  9. Shangera DK, Shara N, Aston CE, Kamboh MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-1073.

  10. Karvonen J, Kauma H, Paivansalo M, Kesaniemi Y: Paraoxonase-1 gene Leu-Met55 and Gln-Arg192 polymorphisms are not associated with carotid artery atherosclerosis in a population-based cohort. Eur J Cardiovasc Prev Rehabil 2004; 6: 511-512.

  11. Sanghera DK, Saha N, Kamboh MI: The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998; 136: 217-223.

  12. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, et al: PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002; 32: 9-15.

  13. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Ritcher RJ, Schellenberg GD, et al: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-2447.

  14. Jarvik GP, Hatsukami TS, Carlson C, Ritcher RJ, Jampsa R, Brophy VH, et al: Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 1465-1471.

  15. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.

  16. Eckerson HW, Romson J, Wyte C, La Du BN: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227.

  17. Adkins S, Gan KN, Mody M, LaDu B: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.

  18. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76.

  19. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J: Four paraoxonase polymorphism in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet 2004; 363: 389-395.

  20. Rojas-García AE, Solís-Heredia MJ, Piña-Guzman L, López-Carrillo L, Quintanilla-Vega B: Genetic polymorphism and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 2005; 205: 282-289.

  21. Gamboa R, Zamora J, Rodriguez-Perez JM, Fragoso JM, Cardoso G, Posadas-Romero C, et al: Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile. Exp Mol Pathol 2006; 80: 85-90.

  22. Vargas-Alarcón G, Zamora J, Sánchez-García S, Rodriguez-Pérez, M, Cardoso G, Posadas-Romero C: Angiotensin-I-converting enzyme (ACE) insertion/deletion polymorphism in Mexican patients with coronary heart disease. Association with the disease but not with lipids levels. Exp Mol Pathol 2006; 81: 131-135.

  23. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind B: A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 1986; 256: 2372-2377.

  24. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterease polymorphism. Am J Human Genet 1983; 35: 1126-1138.

  25. Gan KL, Smolen A, Eckerson HW, La Du BN: Protein purification of human serum paraoxonase/arylesterease. Evidence for one esterease catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.

  26. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 1: 1215.

  27. Motti C, Dessy M, Gnasso A, Irace C, Indigeno P, Angelucci CB, et al: A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphism. Atherosclerosis 2001; 158: 35-40.

  28. Browne RW, Koury ST, Marion S, Wilding G, Muti P, Trevisan M: Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem 2007; 53: 310-317.

  29. Blatter MC, James RW, Messmer S, Barja F, Pometta D: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211: 871-879.

  30. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN: Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999; 19: 330-335.

  31. Sviridov D, Nestel PJ: Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007; 18: 157-163.

  32. Watanabe H , Söderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, et al: Decreased high-density lipoprotein (HDL) particle size, preß-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006; 26: 897-902.

  33. Morgan J, Carey C, Lincoff A, Capuzzi D: High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359-365.

  34. McEleveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH: Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-673.

  35. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against low-density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.

  36. Ruiz J, Blanche H, James RW, Garin MJ, Vaisse C, Charpentier G, et al: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-887.

  37. Mackness MI, Harty D, Bhatnagar D, Winocour TH, Arrol S, Ishola M, et al: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.

  38. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-2088.

  39. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy V, Ritcher RJ, et al: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22: 1329-1333.

  40. Senti M, Tomas M, Anglada R, Elosua R, Marrugat J, Covas MI, et al: Interrelationship of smoking, paraoxonase activity and leisure-time physical activity: a population based-study. Eur J Intern Med 2003; 14: 178-184.

  41. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, Mutanen M: Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002; 160: 425-432.




2020     |     www.medigraphic.com